Revvity, Inc.
$6.6K 5 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Wenzel Spine, Inc.
Wenzel Spine, Inc. reported $6,470.08 across General Payments, Research, and Ownership to 54 physicians and teaching hospitals across 54 transactions.
- $6.5K Below-median payer
- All-tracks total
- 54 Below-median volume
- Transactions
- 54 Below-median reach
- Recipients
- −$29.1K
- General Payments vs PY2023
Wenzel Spine, Inc. reported $6,470.08 across all CMS Open Payments tracks (General + Research + Ownership) to 54 physicians and teaching hospitals in Program Year 2024 - ranking #1689 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $6,470.08, averaging $119.82 per recipient.
How Wenzel Spine, Inc.'s $6.5K all-tracks total breaks down
Wenzel Spine, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer wenzel-spine-inc Wenzel Spine, Inc.
$6.5K · #1689/1,925 · 0.0% industry · PY2024
- TOT $6.5K
- RANK #1689
- SHARE 0.0%
- TXN 54
- RCP 54
- CAT 2
- GEN $6.5K
- ΔGEN −$29.1K
- TOP1 35.1%
- PY 2024
Volume peers
Nearest volume peer: Revvity, Inc. ($6.6K)
Wenzel Spine, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Wenzel Spine, Inc.'s CMS-reported General Payments decreased by $29.1K (−81.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: WENZEL SPINE, INC.PY2023: WENZEL SPINE, INC.PY2024: Wenzel Spine, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $35,542.32
- PY2024
- $6,470.08
What the Data Shows for Wenzel Spine, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Wenzel Spine, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Food and Beverage" leads the 2-category general-payment breakdown below at $4.1K (63.5% of General Payments, 49 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Food and Beverage" leads Wenzel Spine, Inc.'s 2-category general-payment breakdown at $4.1K, 63.5% of the reported total.
How Wenzel Spine, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $4.1K | 49 | 63.5% |
| Travel and Lodging | $2.4K | 5 | 36.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,825.61 (59.1%) of $6,470.08 in this company's General Payments records across 34 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Wenzel Spine, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Louis Saeger
$2,273.91 across 8 reported transactions
- 2
Aaron Calodney
$612.13 across 3 reported transactions
- 3
Adam Lewis
$326.30 across 3 reported transactions
- 4
Sven Hochheimer
$307.83 across 2 reported transactions
- 5
Armond Levy
$305.44 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Wenzel Spine, Inc. ranks #1689 of 1,925 by total payments (bottom 12% by spend) but is notably more concentrated than that alone would suggest -- #871 of 1,838 by HHI (top 47% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Joint Restoration Foundation, Inc. : $130.0K total payments, HHI 1495
- Werfen USA LLC : $53.8K total payments, HHI 1491
- Helena Laboratories Corporation : $3.7K total payments, HHI 1489
- Ascend Therapeutics US, LLC : $74.6K total payments, HHI 1486
- curasan, Inc. : $621.57 total payments, HHI 1486
- Calyxo, Inc. : $311.2K total payments, HHI 1484
- Wenzel Spine, Inc. (this company) : $6.5K total payments, HHI 1484
- Ossur Americas, Inc. : $259.2K total payments, HHI 1476
- Nexus CMF, LLC : $69.0K total payments, HHI 1476
- Vertex Pharmaceuticals Incorporated : $6.9M total payments, HHI 1475
- Theragen, Inc. : $28.8K total payments, HHI 1475
- Ferring Pharmaceuticals AS : $71.5K total payments, HHI 1474
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Wenzel Spine, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Wenzel Spine, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Wenzel Spine, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Medical Graphics Corporation
$6.4K 4 recipients
Compare payment profiles
Carbon Medical Technologies, Inc.
$6.6K 0 recipients
Compare payment profiles
Catalent Pharma Solutions, LLC
$6.3K 4 recipients
Compare payment profiles
Eurofins Viracor, LLC
$6.3K 85 recipients
Compare payment profiles
SIGN Fracture Care International
$6.8K 15 recipients
Compare payment profiles
Put this to use
Wenzel Spine, Inc. ranks #1689 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Wenzel Spine, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.